While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market. Some of the most interesting insights from our study are presented below.
A Mushrooming Area For Researchers, Ready For Strong Commercial Growth With more than 10,000 patents filed in the last decade alone, the ADC market continues to garner significant interest within the biopharmaceutical industry.
The Promising Clinical Pipeline Offers A Variety Of Novel Opportunities
The pipeline, featuring product candidates that target various antigens with different warheads, is anticipated to present several opportunities in the near future
Well-Known Players Have Steadily Driven Innovation
Innovation in this domain is presently focused on exploring different targets, more potent payloads and stable linkers to tap opportunities across various oncological indications.
Specifically, Novel Conjugation Approaches Have Recently Surfaced
Several novel conjugation approaches have also been developed and implemented to enhance the stability and therapeutic indices of ADC molecules.
Extensive Clinical Research, Offering Valuable Data Insights, Continues To Hold The Key
Ongoing improvements in clinical research have revealed better insights on dosing and enabled more efficient MTD estimations.
Led by KOLs from Across the Globe, We Believe The Promise Will Evolve Significantly
The field has evolved under the guidance of several researchers who have emerged as key opinion leaders.
Venture Capital Funding, As Before, Will Be One Of The Primary Enablers
Well funded start-ups are actively contributing to drug development efforts while the more established players continue to enhance their offerings through partnerships
The Market’s Rapid Growth, Both In The Short-Term And Long-Term…
Post the approval and launch of multiple late-phase product candidates, the market is expected to grow at a rapid pace.
… Will Be Driven by Rapid Ongoing Advances
Advances in payload and linker technologies are likely to result in better opportunities in the long term as more drugs get commercialized for a diverse range of indications
Several Stakeholders, Including CMOs, Will Benefit From The Impending Growth Wave
Well funded start-ups are actively contributing to Antibody Drug development efforts while the more established players continue to enhance their offerings through partnerships.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.